Antonio De Rosa
Padova, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.
Journal: ESMO gastrointestinal oncology
Published: May 22, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.
Journal: Targeted oncology
Published: September 18, 2025
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
Journal: Hepatology (Baltimore, Md.)
Published: September 02, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: August 13, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients.
Journal: ESMO open
Published: June 18, 2025
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).
Journal: Therapeutic advances in medical oncology
Published: March 31, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: March 31, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Journal: Oncology
Published: March 25, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Journal: Journal of the National Cancer Institute
Published: March 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Journal: International journal of cancer
Published: January 29, 2025
Last Updated: 09/26/2026